Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7589140 | 0.77 | CRHR1 (0.40) | KMT2ACRHR1PDE4APDE4BPDE4C | |
| SCHEMBL29127378 | 0.76 | SMN1; SMN2 (0.47) | KMT2APDE4DADORA3L3MBTL1SMN1; SMN2 | |
| SCHEMBL7590408 | 0.72 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL8174220 | 0.71 | HSD17B10 (0.47) | PDE4DL3MBTL1SMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL7868719 | 0.70 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL22599461 | 0.68 | SMN1; SMN2 (0.45) | KMT2APDE4DSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL19451738 | 0.67 | KMT2A (0.46) | KMT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31094782 | 0.65 | KMT2A (0.46) | KMT2APDE4BNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20944539 | 0.65 | KMT2A (0.44) | KMT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7227582 | 0.65 | ALDH1A1 (0.44) | KMT2ACRHR1ADORA3L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6469041-B2 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-10-22 | — | — | US | disclosed |
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | NEUROGEN CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-6300360-B1 | FOR THERAPY OF STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6127399-A | TREATING POST TRAUMATIC STRESS DISORDER AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-5973152-A | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands | NEUROGEN CORPORATION | 1999-10-26 | — | — | US | disclosed |
| EP-0941223-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5760225-A | DIAGNOSIS AND TREATMENT OF STRESS DISORDERS AND DEPRESSION | NEUROGEN CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| WO-1998021200-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | CRH, CRHR1, CRHR2 | KMT2A 3948/4885CRHR1 2/4885PDE4A 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.